X0202 SCHEDULE 13G 0001105806 XXXXXXXX LIVE Common Stock 05/01/2026 0001420565 Rein Therapeutics, Inc. 00887A204 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 Rule 13d-1(c) LYTTON LAURENCE W X1 4500000.00 0.00 4500000.00 0.00 4500000.00 N 5.8 IN The percentage reported herein is calculated based on 78,039,032 shares of Common Stock outstanding following the completion of the Issuer's issuance and sale of 50,000,000 shares of Common Stock, as reported in the Rule 424(b)(5) Prospectus filed by the issuer on May 4, 2026. Rein Therapeutics, Inc. 12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758 Laurence W. Lytton 467 Central Park West New York, NY 10025 USA Y 4,500,000 5.8% 4,500,000 0 4,500,000 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. LYTTON LAURENCE W /s/ Laurence W Lytton 05/06/2026